A Phase I, Multi-Center, Open-Label Study To Assess The Safety, Pharmacokinetics, And Preliminary Efficacy Of An Orally Available Small Molecule, Cc-99282, Alone And In Combination With Anti-Lymphoma Agent In Subjects With Relapsed Or Refractory Non-Hodgk
MD Anderson Study Status
CC-99282, Rituximab, Obinutuzumab, Tafasitamab, Tazemetostat
The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-99282 alone and in combination with anti-lymphoma agents in participants with relapsed or refractory non-Hodgkin's lymphomas.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
For general questions about clinical trials: